Comparative Pharmacology
Head-to-head clinical analysis: FINASTERIDE AND TADALAFIL versus YESAFILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINASTERIDE AND TADALAFIL versus YESAFILI.
FINASTERIDE AND TADALAFIL vs YESAFILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (cGMP) in smooth muscle.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing a conformational change leading to receptor degradation and inhibition of estrogen-dependent tumor growth.
One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.
10 mg orally once daily.
None Documented
None Documented
Finasteride: 6-8 hours (elderly ~8 hours); Tadalafil: 17.5 hours (enables once-daily dosing).
Terminal elimination half-life of 3–5 hours in healthy adults; prolonged in hepatic impairment (up to 8–10 hours), requiring dose adjustment.
Finasteride: 57% feces, 39% urine (metabolites); Tadalafil: 36% urine, 61% feces (mostly metabolites).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 2% of the dose, with biliary/fecal elimination as the major route.
Category A/B
Category C
PDE5 Inhibitor
PDE5 Inhibitor